Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-15 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-15 Wild-type, N72D Mutant, and IL-15/IL-15RA Complex Proteins High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL-15 Products |
| Heterodimeric Complex | IL-15 / IL-15Rα Sushi Domain-Fc Fusion Theoretical MW verified. Stable complex for trans-presentation studies. |
View IL-15 Products |
| Receptor Alpha | IL-15Rα (IL15RA) / Sushi Domain Protein For agonist complex formation assays. |
View IL-15RA Products |
| Shared Receptor | IL-2/IL-15Rβ (CD122) Protein Selectivity screening vs IL-2 pathway. |
View IL-2/IL-15Rβ Products |
| Common Gamma Chain | γc (IL-2RG) Protein Shared signaling component, essential for cell line construction. |
View IL-2 receptor gamma Products |
| Gene Delivery | IL-15 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL-15 Products |
| Benchmark Control | Research-grade Neutralizing Antibody & Recombinant IL-15 Superagonist (Sequence of N-803) Positive controls for pathway inhibition and comparative assays. |
View IL-15 Products |
| Validator | IL-15 siRNA Set For knockdown verification. |
View IL-15 Products |
| Related Target A | IL-2 Shared receptor signaling (IL-2/15Rβγc) for comparative selectivity screening. |
View IL-2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Superagonist vs WT potency comparison | Human WT & N72D mutant proteins available with >95% purity; identical HEK293 host for batch consistency. |
| Trans-presentation / Complex kinetics | IL-15Rα sushi domain pre-complexed antigen; verified by SEC-HPLC theoretical MW. |
| Receptor Complex Stability & Half-Life | Pre-formed IL-15/IL-15RA Sushi Domain complexes, rigorously verified by Theoretical MW and High Purity (>95%). |
| Cross-reactivity with IL-2 pathway (shared βγc) | Homolog panel proteins strictly verified by mass spec; Human IL-2 and IL-15 panel available. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available, Sequence Verified for reliable PK modeling. |
| High-Concentration Stability (Sub-Q) | Aggregate-free prep, endotoxin controlled (<0.01 EU/µg), suitable for viscosity testing at 50-100 mg/mL. |
| Cell-Based Assay Baseline Noise | Endotoxin Controlled (<1 EU/µg) and HEK293 Expressed for native glycosylation, ensuring clean data without artefactual activation. |
| Biological Activity Standardization | CTLL-2 cell proliferation assay compatible; validated siRNA for specificity controls. |
| Lack of Controls | Clinical benchmark complexes, biosimilar antibodies, and siRNA included for specificity checks. |
Live IL-15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-15 therapeutics is intensifying, with major players shifting focus from systemic IL-2 mimetics to engineered superagonists, immunocytokines, and tumor-targeted fusions. Unlike IL-2, IL-15 does not expand regulatory T cells (Tregs) and avoids capillary leak syndrome, making it an ideal candidate for driving CD8+ T cell and NK cell proliferation. As first-generation IL-15 complexes achieve regulatory milestones (e.g., ImmunityBio's N-803 (nogapendekin alfa inbakicept) approved for BCG-unresponsive NMIBC in combination with BCG), the next wave of R&D is explicitly targeting systemic toxicity reduction via conditionally active molecules, PEGylated variants, and cis-targeting bispecifics designed to localize immune activation strictly within the tumor microenvironment. Beyond oncology, IL-15 antagonists are being explored for autoimmune indications such as celiac disease and rheumatoid arthritis. More than 80% of pipeline molecules are engineered formats: superagonists (IL-15/IL-15Rα sushi domain complexes), immunocytokines (anti-PD-L1/IL-15 fusions), conditionally active pro-cytokines (protease-activated), and armored cell therapies (CAR-T/CAR-NK co-expressing IL-15).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Cytokine Complex / Superagonist | ImmunityBio (N-803), Novartis, Altor/Nektar | Bladder Cancer, Solid Tumors | Receptor Kinetics (Need high-purity IL-15/IL-15RA pre-complexed antigens) |
| Immunocytokine (Ab-Fusion) | Roche, Sanofi | Advanced Solid Tumors, Lymphoma | Targeting Validation (Need Endotoxin-controlled native HEK293 proteins) |
| Conditionally Active (Prodrug) | Xilio Therapeutics, CytomX | Metastatic Melanoma, RCC | Cleavage/Activation Assay (Need specific mutant proteins & strict structural fidelity) |
| Antagonist mAb | Amgen (historical), Takeda | Celiac Disease, Autoimmune | Epitope Binning vs Cytokine (Need high-purity IL-15 antigen) |
| Cell Therapy (Armored CAR-T/NK) | Various Biopharma, MD Anderson | Hematologic Malignancies | Expression Validation (Need specific anti-IL-15 benchmark Abs and Lentivirus) |
Research & Development Summary
The IL-15 pathway offers a compelling alternative to IL-2 therapy with superior safety profile (no Treg expansion, lower vascular leak syndrome risk). To support the diverse modalities, TarMart provides a comprehensive and quality-controlled toolkit spanning wild-type/mutant antigens, pre-complexed receptor domains, gene delivery vectors, benchmark antibodies, and validated siRNA. Our HEK293-expressed, endotoxin-controlled (<1 EU/µg) proteins ensure physiologically relevant assay results, whether for receptor kinetics, cross-reactivity screening, or cell-based functional assays. As the field progresses toward TME-targeted delivery and combination regimens (e.g., with PD-1/PD-L1 checkpoint inhibitors), researchers require reagents that exactly match clinical-grade quality—TarMart delivers that consistency.